A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Chia, Stephen K.
Ellard, Susan L.
Miller, Wilson H.
Tsao, Ming S.
Funding for this research was provided by:
Canadian Cancer Society Research Institute (021039)
Text and Data Mining valid from 2017-05-02
11 July 2016
16 March 2017
2 May 2017